Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.46 |
| ▸ | TUBB | P07437 | 5/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458531 | 0.89 | KMT2A (0.50) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1458211 | 0.89 | TPMT (0.59) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL986919 | 0.85 | TPMT (0.61) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL5232828 | 0.84 | CYP3A4 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8080285 | 0.83 | MAPK1 (0.54) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1458634 | 0.82 | MEN1 (0.60) | PKMMAPK1KMT2ANPC1GAA | |
| SCHEMBL9944157 | 0.82 | KMT2A (0.44) | TPMTCA12CA1CA2CA4 | |
| 3,4,5-Trimethoxybenzoic Acid SCHEMBL6592 | 0.82 | TPMT (0.78) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1459275 | 0.81 | TPMT (0.50) | TPMTCA12CA1CA2CA4 | |
| SCHEMBL1458060 | 0.81 | TSHR (0.51) | TPMTKMT2AHTTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2473479-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | King's College London (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | TPMT 1990/4885CA12 2933/4885CA1 2904/4885 |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | TPMT 2218/4885CA12 4325/4885CA1 1797/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | TPMT 1907/4885CA12 4529/4885CA1 4598/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | TPMT 2218/4885CA12 4325/4885CA1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.